Navigation Links
Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors-

NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. today announced the presentation of data validating the clinical antiviral activity of one of Achillion's NS4A antagonists, ACH-806, for the treatment of hepatitis C virus (HCV) infection at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). In three separate presentations, Achillion researchers discussed the potent antiviral activity in HCV-infected subjects, synergy with other classes of HCV inhibitors, and the unique mode of action of a NS4A antagonist. Achillion has shown that blocking NS4A, a viral protein that binds to a portion of HCV protease, inhibits HCV replication. This program is part of a collaboration and exclusive license agreement with Gilead Sciences for the research, development and commercialization of compounds for the treatment of chronic HCV.

In a late-breaker session on April 14th at 5:00 PM, John Pottage, M.D., Senior Vice President and Chief Medical Officer at Achillion, discussed clinical data in a presentation titled, "Short-term Antiviral Activity and Safety of ACH-806 (GS-9132), an NS4A Antagonist, in HCV Genotype 1 Infected Individuals." The randomized, double-blind, placebo-controlled dose-escalation trial measured the antiviral activity, safety and pharmacokinetics of 300 mg of ACH-806 or placebo, dosed orally twice daily as a monotherapy over 5 days. The mean change in HCV RNA (log10) at day 5 was a decrease of 0.91 from baseline for treated subjects versus an increase of 0.05 for control subjects. Elevations in serum creatinine (a marker of kidney function) were observed in ACH-806 treated subjects and were reversible after completion of dosing.

"This study provides the first demonstration of human antiviral a
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... , Some form of electronic hematology analyzer is ... blood cell count is usually the first screening test ... infection, and monitor cancer patients during the course of ... this workhorse device, and surprising to learn its origins., ...
... ,Medical conventions are challenged every day. Already in ... and the gold standard in breast cancer treatment ... the latest casualty of medical innovation., ,For years, ... of high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein ...
Cached Medicine Technology:Hematology Analyzers Simple, Sophisticated Technology Serving All Patients 2Hematology Analyzers Simple, Sophisticated Technology Serving All Patients 3Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal 2Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal 3
(Date:7/13/2014)... HealthDay Reporter FRIDAY, July 11, ... for people with diabetes is being developed to measure sugar ... report. Scientists at Brown University in Providence, R.I., created ... uses light, metal and a special enzyme that changes color ... have to prick their fingers to draw blood to check ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4
... barrier to health care is unauthorized prescription drug switching, ... founder of the Minority Health Institute.In his keynote address ... Williams said the U.S. would be better served if ... patient,s needs without artificial barriers set by outside ...
... 28 This weekend, Americans will experience the stress-reducing ... ), a musical meditation that gets diverse groups of ... Heart of Rhythm and Sound," will take place on ... Rudramandir center, in Berkeley, California."Almost effortlessly, people with no ...
... Prevention efforts ,have run out of steam, expert says, , , ... risk of dying prematurely? Don,t smoke and keep a healthy ... about one in five deaths among U.S. adults, according to ... to be linked with premature death, the magnitude of the ...
... Monoxide Exposure Detection Following Disasters, Agency Unanimously Approves ... 28 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today ... added to the Federal Emergency Management Agency,s (FEMA) ...
... Wash., April 28 Verathon(R) is pleased to announce ... Designed with Urologists in mind, the BVM 9500 ... quickly and noninvasively to help diagnose bladder dysfunction, including ... This new addition to the BladderScan(R) BVI 9000 ...
... of Our Society?TACOMA, Wash., April 28 What if ... looking to improve their lives can now prime their ... audio collection. The iDrug employs a technique called brain ... in order to "reprogram" their subconscious minds with new ...
Cached Medicine News:Health News:Barriers to Health Care, Prescription Choice Hurt Patients, Leading Doctor Says 2Health News:The Art of Rhythm Meditation: Zen Buddhist Goes Global with TaKeTiNa Rhythm Process 2Health News:1 in 5 U.S. Deaths Attributed to Smoking, High BP 2Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 2Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 3Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 4Health News:FEMA Adds Masimo Rad-57(R) Pulse CO-Oximeter(TM) to Required Medical Equipment List 5Health News:Verathon(R) Introduces BladderScan(R) BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction 2Health News:Verathon(R) Introduces BladderScan(R) BVM 9500 Bladder Volume Instrument To Help Urologists Diagnose Bladder Dysfunction 3Health News:iDrug Technology Hopes to Promote Economic Stimulus at the Subconscious Level of Every Citizen 2
... Eppendorf expands its line of ... easy-to-use microcentrifuge features a certified aerosol-tight ... bowl design to reduce noise., ,Model ... offering optional rotors to accommodate microcentrifuge ...
The new BioZ Dx incorporates the world's most advanced impedance cardiography (ICG) technology and powerful reporting features to quickly and easily provide noninvasive hemodynamic parameters....
... Varicella-Zoster (VZ) test system is ... semi-quantitative detection of VZ IgG ... the indirect fluorescent antibody (IFA) ... or confirm a recent infection ...
Inquire...
Medicine Products: